News & Events
Published On: 6/15/2021
TARGET-NASH Study Finds Statins Underutilized in Patients with NAFLD and At-Risk of Heart Disease
DURHAM, N.C., June 15, 2021 /PRNewswire/ -- Just over half (56%) of patients enrolled in TARGET-NASH with non-alcoholic fatty liver disease (NAFLD) and with at least one indication for guideline-recommended use of a statin are taking one despite their higher risk of heart disease, according to new research published in Clinical Gastroenterology & Hepatology (doi: 10.1016/j.cgh.2021.03.031; epub ahead of print). The analysis from the long-term observational study TARGET-NASH was sponsored by Target RWE, a leading real-world evidence (RWE) solutions company for the healthcare industry.
Global prevalence of NAFLD is estimated at 25%, and diagnoses have increased over the past two decades.1 This increasing prevalence, paired with high risk of heart disease that NAFLD patients face, sets the stage for a growing public health concern.
Statins are a class of medications commonly prescribed to reduce the risk of heart disease. But they are often under-prescribed among patients with liver disease due to concerns over causing further liver damage.2,3 However, research has shown that statins are safe among patients with liver disease, including those with compensated cirrhosis,4 and use is associated with lower mortality, lower risk of further liver deterioration, and possibly lower hepatocellular carcinoma.5,6
"Providers are grappling with an aging population, paired with serious and comorbid chronic conditions like heart disease and NAFLD. This real-world evidence from the TARGET-NASH study provides much-needed insight into the course of treatment for patients with NAFLD who are at risk of cardiovascular disease," said Mary Thomson, MD, MSC, Assistant Professor of Medicine, Division of Gastroenterology, Hepatology, and Nutrition, University of Minnesota Medical School, and lead co-author.
"Our results found guideline-recommended statins remain underutilized and were not prescribed in 40% of NAFLD patients with clear indications," said Anna S. Lok, MD, Professor of Internal Medicine and Director of Clinical Hepatology, University of Michigan. "Educating providers and patients on statin safety and benefits to prevent cardiovascular disease, especially at-risk NAFLD patients, will be imperative in improving outcomes of patients with NAFLD who are at risk of both cardiovascular and liver-related mortality."
The TARGET-NASH manuscript assessed prevalence and patient factors associated with indicated statin use in patients with NAFLD, NASH, compensated cirrhosis, and decompensated cirrhosis. Results found older patients, including those with high cholesterol, diabetes, or history of cardiovascular disease, were more likely to be on a statin. Women were less likely to be on an indicated statin compared to men, and there was a smaller proportion of patients with cirrhosis using a statin compared to those with milder disease. Prevalence and factors associated with statin use among patients with non-alcoholic fatty liver disease in TARGET-NASH analyzed 2,214 patients across 60 U.S. sites with at least one statin indication.
About Target RWE
Target RWE is a leading health evidence solutions company that generates innovative real-world evidence (RWE) and provides scientific intelligence tools and solutions for pharmaceutical, biotechnology, and other healthcare partners. Specifically designed to address the complexities of the natural history of disease, the drug development process and treatments in real-world settings, Target RWE builds regulatory-grade clinical data sets and applies state of the science epidemiologic methods to produce RWE about patients with specific conditions, symptoms, and therapies used in usual clinical practice.
Target RWE's regulatory-grade data sets and evidence, modern epidemiological methods, and sound scientific principles rendered as software can be utilized to better health outcomes, inform patient health guidelines, and improve overall quality of care. For more information, visit www.targetrwe.com.
984.234.0268 ext 205
04/04/2022Target RWE Primary Biliary Cholangitis (PBC) Encore Data Presented at APASL 2022
03/29/2022Large Real-World Study Uncovers Higher Prevalence of Non-Alcoholic Fatty Liver Disease Markers, Liver Biopsy, and Cirrhosis in Children
03/08/2022TARGET-IBD Study Reveals Nearly a Third of Patients with Inflammatory Bowel Disease Did Not Undergo Objective Assessment Prior to Biologic Dose Change, Discontinuation
12/15/2021Target RWE Dermatology Study Data Shared at 3rd Annual RAD Conference
11/30/2021Target RWE Appoints Derek Evans as President